The addition of cetuximab showed a trend toward improved DFS ( hazard ratio -LSB- HR -RSB- , @ ; @ % CI , @-@ @ ; P = @ ) and OS ( HR , @ ; @ % CI , @-@ @ ; P = @ ) in the overall group , regardless of KRAS status , and in patients with wild type KRAS .